---
created: '2026-02-08T19:25:13.066825Z'
description: The cellular degradation and recycling system that removes damaged organelles
  and protein aggregates. Dysfunction contributes to accumulation of toxic proteins
  in neurodegenerative diseases.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/Pathway/autophagy-lysosomal-pathway/
slug: autophagy-lysosomal-pathway
tags:
- Pathway
- pathway
- neurodegeneration
- autophagy
- lysosome
- proteostasis
title: Autophagy-Lysosomal Pathway
type: Pathway
updated: '2026-02-08T19:25:13.066825Z'
---

# Autophagy-Lysosomal Pathway

## Overview
The autophagy-lysosomal pathway (ALP) is the primary cellular system for degrading and recycling long-lived proteins, protein aggregates, and damaged organelles. Autophagy ("self-eating") delivers cargo to lysosomes for breakdown. In neurons, which are post-mitotic and cannot dilute toxic proteins through cell division, a functional ALP is critical for survival. Dysfunction of this pathway is implicated in virtually all neurodegenerative diseases.

## Types of Autophagy

### Macroautophagy
- Most studied form
- Double-membrane vesicles (autophagosomes) engulf cargo
- Autophagosomes fuse with lysosomes
- Bulk degradation

### Chaperone-Mediated Autophagy (CMA)
- Selective degradation via KFFERQ-like motifs
- HSC70 recognizes substrates
- LAMP2A receptor on lysosome
- Direct translocation into lysosome

### Microautophagy
- Direct invagination of lysosomal membrane
- Less characterized in neurons

## Macroautophagy Steps

### 1. Initiation
- **ULK1 complex**: Senses nutrient/energy status
- mTORC1 inhibition activates autophagy
- AMPK activation promotes autophagy

### 2. Nucleation
- **Beclin-1 complex**: VPS34, ATG14
- PI3P production
- Omegasome formation

### 3. Elongation
- **ATG5-ATG12-ATG16L complex**
- **LC3-II**: Lipidated LC3 marks autophagosome membrane
- Membrane expansion

### 4. Cargo Recognition
- **p62/SQSTM1**: Ubiquitin-binding adaptor
- **OPTN, NBR1, NDP52**: Additional adaptors
- Selective autophagy of aggregates (aggrephagy)

### 5. Fusion
- Autophagosome-lysosome fusion
- SNARE proteins, Rab7
- Autolysosome formation

### 6. Degradation
- Lysosomal hydrolases (cathepsins)
- Acidic pH (~4.5)
- Nutrient recycling

## Regulation

### Inhibitors of Autophagy
- **mTORC1**: Master negative regulator
- Fed state, growth factors
- High amino acids

### Activators of Autophagy
- **AMPK**: Energy sensor; activates autophagy
- Starvation, caloric restriction
- Exercise
- Rapamycin (mTOR inhibitor)
- Spermidine, resveratrol

## Dysfunction in Disease

### Alzheimer's Disease
- Autophagosome accumulation
- Lysosomal acidification defects (presenilin)
- APOE4 impairs autophagy
- Aβ and tau accumulate

### Parkinson's Disease
- PINK1/Parkin mitophagy defects
- α-synuclein impairs autophagy
- GBA1 mutations → lysosomal dysfunction
- LRRK2 affects autophagy

### Huntington's Disease
- Mutant huntingtin impairs cargo recognition
- p62 dysfunction
- Autophagosome formation defects

### ALS
- TDP-43, FUS, C9orf72 affect autophagy
- Stress granule accumulation
- Autophagy receptor mutations

### Lysosomal Storage Disorders
- Enzyme deficiencies
- Substrate accumulation
- Secondary autophagy block

<!-- NEO4J_CONTENT_START -->
## Relationships
### Related
- → [[Parkinsons_Disease]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[Amyloid_Cascade]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[Ubiquitin-Proteasome_System]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[Intermittent_Fasting]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[Huntingtons_Disease]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[mTOR_Signaling]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[Tau_Phosphorylation]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[Alpha-Synuclein_Aggregation]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[Alzheimers_Disease]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[Caloric_Restriction]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[Frontotemporal_Dementia]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[Amyotrophic_Lateral_Sclerosis]] (entity)
```yaml
last_modified: '2026-01-26T06:48:40.063840'
source: obsidian
```
- → [[Tau_Phosphorylation]] (pathway)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[AMPK]] (protein)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[mTOR_Signaling]] (entity)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Ubiquitin-Proteasome_System]] (entity)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- ← [[Alpha-Synuclein_Aggregation]] (pathway)
```yaml
last_modified: '2026-01-26T07:08:10.957081'
source: obsidian
```
- → [[Amyloid_Cascade]] (pathway)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Alzheimers_Disease]] (condition)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Frontotemporal_Dementia]] (condition)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Mitophagy]] (pathway)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Rapamycin]] (drug)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Amyotrophic_Lateral_Sclerosis]] (condition)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Spermidine]] (supplement)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Exercise]] (intervention)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Parkinsons_Disease]] (condition)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Caloric_Restriction]] (intervention)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Intermittent_Fasting]] (intervention)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Alpha-Synuclein_Aggregation]] (pathway)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
- → [[Huntingtons_Disease]] (condition)
```yaml
last_modified: '2026-01-26T07:08:11.341134'
source: obsidian
```
<!-- NEO4J_CONTENT_END -->
## Relationships

### Neurodegenerative Diseases
- → [[Alzheimer's Disease]] (condition) - *Lysosomal dysfunction*
- → [[Parkinson's Disease]] (condition) - *Mitophagy defects*
- → [[Huntington's Disease]] (condition) - *Cargo recognition impaired*
- → [[Amyotrophic Lateral Sclerosis]] (condition) - *Autophagy gene mutations*
- → [[Frontotemporal Dementia]] (condition) - *C9orf72, GRN involvement*

### Related Pathways
- → [[Mitophagy]] (pathway) - *Selective mitochondria autophagy*
- → [[Ubiquitin-Proteasome System]] (pathway) - *Complementary degradation*
- → [[mTOR Signaling]] (pathway) - *Master regulator*
- ← [[AMPK]] (protein) - *Autophagy activator*

### Pathological Cargo
- ← [[Alpha-Synuclein Aggregation]] (pathway) - *Cleared by autophagy*
- ← [[Tau Phosphorylation]] (pathway) - *Tau degraded by autophagy/CMA*
- ← [[Amyloid Cascade]] (pathway) - *Aβ cleared by autophagy*

### Interventions
- ← [[Caloric Restriction]] (intervention) - *Potent autophagy inducer*
- ← [[Exercise]] (intervention) - *Activates AMPK, autophagy*
- ← [[Rapamycin]] (drug) - *mTOR inhibitor; autophagy inducer*
- ← [[Spermidine]] (supplement) - *Autophagy enhancer*
- ← [[Intermittent Fasting]] (intervention) - *Autophagy activation*

## Therapeutic Strategies

### Autophagy Inducers
- Rapamycin/rapalogs (mTOR inhibition)
- AMPK activators (metformin, AICAR)
- Trehalose (mTOR-independent)
- Spermidine

### Lysosomal Enhancement
- Acidification restoration
- Enzyme replacement (LSDs)
- Gene therapy for lysosomal enzymes

### Substrate Reduction
- Reduce toxic protein production
- Antisense oligonucleotides
- Small molecule aggregation inhibitors

### Lifestyle
- Caloric restriction mimetics
- Exercise prescription
- Intermittent fasting protocols
- Time-restricted eating

## Biomarkers

### Autophagy Markers
- LC3-II/LC3-I ratio
- p62/SQSTM1 levels
- Autophagy flux assays

### Lysosomal Markers
- Cathepsin activity
- LAMP1/LAMP2 levels
- Lysosomal pH

## References
1. **Review**: Menzies, F.M., et al. (2017). "Autophagy and neurodegeneration." *Molecular Cell*.
2. **Parkinson's**: Nguyen, M., et al. (2019). "Autophagy and Parkinson's disease." *Journal of Parkinson's Disease*.
3. **Therapeutics**: Rubinsztein, D.C., et al. (2015). "Autophagy modulation as a potential therapeutic target." *Nature Reviews Drug Discovery*.